Drupal.behaviors.print = function(context) {window.print();window.close();}>
SomaGenics Rides on Strong Preclinical Data to Move HCV Drug into Phase I Next Year
September 29, 2011
SomaGenics Rides on Strong Preclinical Data to Move HCV Drug into Phase I Next Year
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Somagenics Holds Back on HCV Clinical Trial Amid Advances by Other Drugmakers
November 29, 2012 / Gene Silencing News
Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News
UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News
Benitec Selects Duke as Site for HCV Drug Trial
March 28, 2013 / Gene Silencing News
Regulus Continues to Aim for Two INDs in 2014, Expects miRNA Biomarker Data in Q3
February 21, 2013 / Gene Silencing News